Literature DB >> 4993767

Atopic hypersensitivity to L-asparaginase. Resistance to immunosuppression.

A Khan, J M Hill.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 4993767     DOI: 10.1159/000230429

Source DB:  PubMed          Journal:  Int Arch Allergy Appl Immunol        ISSN: 0020-5915


× No keyword cloud information.
  6 in total

Review 1.  Hypersensitivity reactions from antineoplastic agents.

Authors:  R B Weiss; J R Baker
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

Review 2.  Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future.

Authors:  Vassilios I Avramis; Eduard H Panosyan
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 3.  Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.

Authors:  Brian A Baldo; Nghia H Pham
Journal:  Cancer Metastasis Rev       Date:  2013-12       Impact factor: 9.264

4.  Lymphocyte transformation studies in drug hypersensitivity.

Authors:  R J Warrington; K S Tse
Journal:  Can Med Assoc J       Date:  1979-05-05       Impact factor: 8.262

5.  Comparative immunogenicity and structural analysis of epitopes of different bacterial L-asparaginases.

Authors:  Vadim S Pokrovsky; Marat D Kazanov; Ilya N Dyakov; Marina V Pokrovskaya; Svetlana S Aleksandrova
Journal:  BMC Cancer       Date:  2016-02-11       Impact factor: 4.430

Review 6.  Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia.

Authors:  Vassilios I Avramis; Prakash Nidhi Tiwari
Journal:  Int J Nanomedicine       Date:  2006
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.